TY - JOUR
T1 - Travoprost versus latanoprost combinations in glaucoma
T2 - Economic evaluation based on visual field deficit progression
AU - Schmier, Jordana K.
AU - Halpern, Michael T.
AU - Covert, David W.
AU - Robin, Alan L.
N1 - Funding Information:
Declaration of interest: Funding for this research, as well as editorial assistance and production, was provided by Alcon Research, Ltd. One of the authors (DWC) is an employee of Alcon.
PY - 2006/9
Y1 - 2006/9
N2 - Objective: Changes in intraocular pressure (IOP) are known to be related to visual field deficit progression, although multiple models of this relationship exist. In addition, visual functioning is known to affect medical costs. The objective of this study was to project visual field deficit progression and subsequent costs based on clinical trial data. Research design and methods: Using data from a randomized, 12-month, double-masked study, we compared the use of a fixed combination of travoprost 0.004%/timolol 0.5% (T/T) versus a fixed combination of latanoprost 0.005%/timolol 0.5% (L/T) on visual field deficit progression and associated costs. We applied published algorithms linking IOP to visual field changes to calculate the likelihood of visual field deterioration by treatment group. Differences in medical care costs were estimated using guideline-recommended practice patterns, Medicare hospital costs, and published estimates of differences in hospitalization by visual functioning. Main outcome measures: Increase in visual field deficit progression rates, increase in annual hospital days per subject, and increase in annual hospital, outpatient, and total costs per subject. Results: Predicted visual field deficit progression for T/T patients was less than that for L/T patients (not statistically significant). Projected annual medical care costs were $43 lower for T/T vs. L/T patients. Conclusions: By applying published algorithms linking IOP to visual field changes, this study projected long-term visual field deficit and associated costs. Use of a fixed travoprost/timolol solution may lead to less long-term visual field deficit progression and lower annual medical care costs than a fixed latanoprost/timolol solution. Discussion: The use of clinical trial data may limit the applicability of these findings. However, this analysis of direct medical costs only is likely a conservative estimate of the costs associated with visual field deficits.
AB - Objective: Changes in intraocular pressure (IOP) are known to be related to visual field deficit progression, although multiple models of this relationship exist. In addition, visual functioning is known to affect medical costs. The objective of this study was to project visual field deficit progression and subsequent costs based on clinical trial data. Research design and methods: Using data from a randomized, 12-month, double-masked study, we compared the use of a fixed combination of travoprost 0.004%/timolol 0.5% (T/T) versus a fixed combination of latanoprost 0.005%/timolol 0.5% (L/T) on visual field deficit progression and associated costs. We applied published algorithms linking IOP to visual field changes to calculate the likelihood of visual field deterioration by treatment group. Differences in medical care costs were estimated using guideline-recommended practice patterns, Medicare hospital costs, and published estimates of differences in hospitalization by visual functioning. Main outcome measures: Increase in visual field deficit progression rates, increase in annual hospital days per subject, and increase in annual hospital, outpatient, and total costs per subject. Results: Predicted visual field deficit progression for T/T patients was less than that for L/T patients (not statistically significant). Projected annual medical care costs were $43 lower for T/T vs. L/T patients. Conclusions: By applying published algorithms linking IOP to visual field changes, this study projected long-term visual field deficit and associated costs. Use of a fixed travoprost/timolol solution may lead to less long-term visual field deficit progression and lower annual medical care costs than a fixed latanoprost/timolol solution. Discussion: The use of clinical trial data may limit the applicability of these findings. However, this analysis of direct medical costs only is likely a conservative estimate of the costs associated with visual field deficits.
KW - Costs and cost analysis
KW - Disease progression
KW - Glaucoma, open-angle
KW - Health care costs
KW - Visual fields
UR - http://www.scopus.com/inward/record.url?scp=33749032830&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33749032830&partnerID=8YFLogxK
U2 - 10.1185/030079906X121011
DO - 10.1185/030079906X121011
M3 - Article
C2 - 16968577
AN - SCOPUS:33749032830
SN - 0300-7995
VL - 22
SP - 1737
EP - 1743
JO - Current Medical Research and Opinion
JF - Current Medical Research and Opinion
IS - 9
ER -